<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0502233211
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RESOLOR 2 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PRUCALOPRIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        161.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN-CILAG SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN-CILAG SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Amdipharm Mercury (Australia) Pty Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A03AE04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>is used to treat long-term recurring&nbsp; constipation in women in whom laxatives do not work well enough.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>WHEN NOT TO TAKE Resolor&trade;</p><p><strong>Do not take if you: </strong></p><p>&bull;&nbsp; are allergic (hypersensitive) to prucalopride or any of the other ingredients of Resolor&trade;,</p><p>&bull;&nbsp; have severe kidney disease and are&nbsp; on kidney (renal) dialysis,</p><p>&bull;&nbsp; have a torn (perforated) or blocked gut (intestines) or other gut problemssuch as Crohn&rsquo;s disease, ulcerative colitis or toxic megacolon/megarectum.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;WHAT SPECIAL PRECAUTIONS SHOULD YOU TAKE? </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p><p><strong>Take special care with Resolor&trade; if you: </strong></p><p>&bull;&nbsp; have severe kidney problems,</p><p>&bull;&nbsp; have severe liver problems,</p><p>&bull;&nbsp; have a serious medical problem such as: lung or heart problems, cancer or AIDS.</p><p>&nbsp;</p><p>If you have very bad diarrhoea and are taking a contraceptive pill, the contraceptive pill may not work properly and you should talk to your doctor about other contraception methods.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;<strong>Children</strong></p><p>Resolor&trade; should not be given to children under 18 years.</p><p>&nbsp;</p><p>&nbsp;Pregnancy</p><p>If you are of c hild be aring age, you s hould t alk t o your doc tor ab out c ontraception dur ing treatment w ith Resolor&trade;. Resolor&trade; is not r ecommended dur ing pr egnancy.&nbsp; If y ou ar e, pregnant, or you think you may be pregnant, or if you are planning to become pregnant, talk to your doctor about the risks and benefits of taking Resolor&trade;.&nbsp;</p><p>&nbsp;Breast-feeding</p><p>You are advised not to take Resolor&trade; if you are breast- feeding, because small amounts of Resolor&trade; can be passed on to your baby in breast milk. If you are breast-feeding or thinking about breast-feeding talk to your doctor. .</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;Driving or operating machinery</p><p>Resolor&trade; may cause dizziness and tiredness, especially on t he first day of treatment which may make you less alert. Don&rsquo;t drive or use machines unless you are sure you are not affected. &nbsp;</p><p>&nbsp;</p><p>&nbsp;Other medicines</p><p>Please t ell your doc tor or phar macist i f you ar e t aking or ha ve r ecently t aken an y other medicines. This includes medicines that you buy without a prescription or herbal medicines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Resolor&trade; comes in the form of <strong>film coated</strong> <strong>tablets</strong> to be taken by mouth.&nbsp; You can take Resolor&trade; with or without food and drinks, at any time of the day.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Always take Resolor&trade; exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. You should take Resolor&trade; every day for as long as your doctor prescribes it.</p><p>&nbsp;</p><p>Your doctor may check how well Resolor&trade; is working after the first 4 w eeks and r egularly after that.</p><p>&nbsp;</p><p><em>Adults (including people over 65 years) </em>&nbsp;</p><p>The usual dose of Resolor&trade; for adults is one 2 m g tablet once a day . If you are older than 65 years, the usual starting dose is one 1 mg tablet once a day, which your doctor may increase to 2 mg once a day if needed.</p><p>&nbsp;</p><p>Your doctor may also prescribe a lower dose of one 1 mg tablet daily if you have&nbsp; kidney or liver problems.</p><p>&nbsp;</p><p>&nbsp;</p><p>Resolor&trade; is only for adult women and s hould not be taken by children and adol escents up t o 18 years.</p><p>&nbsp;</p><p>If you take more Resolor&trade; than you should</p><p>It is important to keep to the dose as prescribed by your doctor. If you have taken more Resolor&trade; than you should, you may get diarrhoea, headache and/or nausea. If you get diarrhoea, make sure that you drink more water than usual and ask your doctor or pharmacist for further advice.</p><p><strong>&nbsp;</strong></p><p>If you forget to take Resolor&trade;</p><p>If you forget to take a do se, take it as soon as you remember and t hen continue treatment as before. Do not take a double dose to make up for a missed dose.&nbsp;</p><p><strong>&nbsp;</strong></p><p>If you stop taking Resolor&trade;</p><p>If you stop taking Resolor&trade;, your constipation may come back again. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p>Important information about some of the ingredients of Resolor&trade;</p><p>Resolor&trade; contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Resolor&trade; can cause side effects, although not everybody gets them. The side effects usually happen&nbsp; when you first start using Resolor&trade; and usually disappear within a few days..</p><p>&nbsp;</p><p>Very common side effects</p><p>These may affect more than 1 in 10 people</p><p>&bull;&nbsp; Headache</p><p>&bull;&nbsp; Feeling sick (nausea)</p><p>&bull;&nbsp; Diarrhoea&nbsp;</p><p>&bull;&nbsp; Stomach pain</p><p>&nbsp;</p><p>Common side effects</p><p>These may affect up to 1 in 10 people</p><p>&bull;&nbsp; Dizziness</p><p>&bull;&nbsp; Vomiting</p><p>&bull;&nbsp; Disturbed digestion (dyspepsia)</p><p>&bull;&nbsp; Rectal bleeding</p><p>&bull;&nbsp; Windiness (flatulence)</p><p>&bull;&nbsp; Unusual bowel sounds</p><p>&bull;&nbsp; Need to pass urine more often than usual (pollakiuria)</p><p>&bull;&nbsp; Tiredness</p><p>&nbsp;</p><p>Uncommon side effects</p><p>These may affect up to 1 in 100 people</p><p>&bull;&nbsp; Loss of appetite (anorexia)</p><p>&bull;&nbsp; Shaking (tremors)</p><p>&bull;&nbsp; Fever</p><p>&bull;&nbsp; Weakness</p><p>&bull;&nbsp; Pounding heart (palpitations) <strong>If you get a pounding heart, tell your doctor straight away as you may need medical attention. </strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>This medicine c an be k ept f or onl y a l imited per iod. D o not us e Resolor&trade; after t he dat e (month and year) printed after &ldquo;EXP&rdquo;, even if it has been stored properly.</p><p>&nbsp;</p><p>Store in the original blister package in order to protect form moisture. Do not store above 30&ordm;C.</p><p>&nbsp;</p><p>You are advised to return expired medicine to your pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Resolor&trade; is a medicine to treat constipation. The active ingredient is <strong>prucalopride</strong>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One film-coated tablet of Resolor&trade; 1 mg contains 1 mg prucalopride (as prucalopride succinate).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One film-coated tablet of Resolor&trade; 2 mg contains 2 mg prucalopride (as prucalopride succinate).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The other ingredients are:

Lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, hypromellose, triacetin, titanium dioxide (E171), macrogol 3000. The 2 mg tablet also contains iron oxide red (E172), iron oxide yellow (E172), FD&C blue no. 2 aluminium lake (E132)

                         
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Registration holder/Manufacturer:</p><p>[See the outer Package.]</p><p>&nbsp;</p><p>MARKETING AUTHORIZATION HOLDER:</p><p>Shire-Move tis NV, Veedijk 58, B-2300 Turnhout, Belgium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                28 February 2011  
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>لعلاج الإمساك المتكرر الممتد لفترات طويلة في النساء اللاتي لا تحقق معهن الملينات الأخرى تأثيرًا &trade; يُستعمل ريزولور<br />فعالاً بدرجة كافية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناولي هذا الدواء إذا كنتِ:<br />،&trade; &bull; تعانين من حساسية لمادة بروكالوبرايد أو أي من المكونات الأخرى في الدواء ريزولور<br />&bull; تعانين من مرض كلوي حاد وتخضعين لجلسات غسيل كلوي،<br />&bull; تعانين من تمزق (ثقب) أو انسداد في الأمعاء أو مشكلات أخرى في، مثل مرض كرون أو التهاب القولون التقرحي<br />أو تضخم القولون السام/تضخم المستقيم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>في الحالات التالية: &trade; ينبغي الاحتياط بشكل خاص عند تناول ريزولور<br />&bull; إذا كنت تعانين من مشكلات حادة في الكلى،<br />&bull; إذا كنت تعانين من مشكلات حادة في الكبد،<br />&bull; إذا كنت تعانين من مشكلات طبية خطيرة مثل: مشكلات في الرئة أو القلب، سرطان أو الأيدز.<br />إذا كنت تعانين من إسهال حاد جدًا، وتتناولين حبوب منع الحمل، فقد لا تعمل حبوب منع الحمل بشكل صحيح،<br />ويجب عليك التحدث مع الطبيب حول استخدام طرق منع حمل أخرى.<br />الأطفال E<br />للأطفال أقل من 18 سنة. &trade; يجب عدم إعطاء ريزولور<br />الحمل p<br />إذا كنتِ في سن الإنجاب، يجب عليك التحدث مع الطبيب حول وسائل منع الحمل خلال فترة العلاج باستخدام<br />أثناء الحمل. إذا كنت حاملاً، أو تظنين أنك قد تصبحين حاملاً، أو إذا &trade; لا يُوصى باستخدام ريزولور .&trade; ريزولور<br />.&trade; كنت تخططين لتصبحي حاملاً، فينبغي لك التحدث إلى الطبيب حول مخاطر وفوائد تناول ريزولور<br />الرضاعة الطبيعية A<br />إلى طفلك الرضيع من &trade; إذا كنت مرضعة، لأنه يمكن مرور كميات صغيرة من ريزولور &trade; يُنصح بعدم تناول ريزولور<br />خلال حليب الثدي. فإذا كنت مرضعة أو تفكرين في الإرضاع الطبيعي، فتحدثي إلى الطبيب بهذا الشأن.<br />قيادة المركبات أو تشغيل الآلات Y<br />الدوخة والتعب، خاصةً في اليوم الأول من العلاج، وقد يجعلك هذا أقل تنبهًا. تجنبي قيادة المركبات &trade; قد يسبب ريزولور<br />أو استخدام الآلات ما لم تكوني متأكدة من أنك لست متأثر بتلك الأعرض.<br />الأدوية الأخرى T<br />يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناولين أو قد تناولت أي أدوية أخرى مؤخرًا. يشمل هذا الأدوية التي<br />تشترينها دون وصفة طبية أو الأعشاب الطبية.<br />وجرعته &trade; كيفية تناول ريزولور o<br />في شكل أقراص مغطاة بطبقة رقيقة يتم تناولها عن طريق الفم. &trade; يأتي ريزولور<br />مع أو بدون طعام ومشروبات في أي وقت في اليوم. &trade; يمكن تناول ريزولور<br />دائمًا حسب إرشادات الطبيب تمامًا بتمام. ينبغي لك الرجوع إلى الطبيب أو الصيدلي إذا كنت غير &trade; تناولي ريزولور<br />كل يوم طوال المدة التي يصفها لك الطبيب. &trade; متأكدة من كيفية تناول الدواء. ينبغي تناول ريزولور<br />بعد الأسابيع الأربعة الأولى ثم بصفة متظمة بعد تلك المدة. &trade; يمكن للطبيب فحص مدى فعالية ريزولور<br />البالغون (بما في ذلك الأفراد فوق 65 سنة)<br />للبالغين هي قرص واحد 2 ملجم مرة واحدة يوميًا. إذا كنت تجاوزت 65 سنة، &trade; الجرعة المعتادة من ريزولور<br />فالجرعة المعتادة التي تبدأين بها هي قرص واحد 1 ملجم مرة واحدة يوميًا، ويمكن أن يزيدها الطبيب إلى 2 ملجم مرة<br />واحدة يوميًا إذا لزم الأمر.<br />يمكن للطبيب أيضًا وصف جرعة أقل - 1 ملجم يوميًا - إذا كنت تعانين من مشكلات في الكلى أو الكبد.<br />مخصص للنساء البالغات فقط، ولا ينبغي أن يتناوله الأطفال واليافعون حتى سن 18 سنة. &trade; إن دواء ريزولور<br />&trade; في حالة تناول جرعة زائدة من ريزولور<br />فقد تصابين بإسهال و/أو صداع ،&reg; من المهم الالتزام بالجرعة التي يصفها الطبيب. إذا تناولت جرعة زائدة من ريزولور<br />و/أو غثيان. إذا أصبت بإسهال، فتأكدي من تناول كميات كيرة من المياه أكثر من المعتاد، واستشيري الطبيب أو الصيدلي.<br />&trade; في حالة نسيان تناول جرعة ريزولور<br />في حالة نسيان تناول الجرعة، ينبغي أخذها على الفور حال تذكرها ثم متابعة استخدامها كالمعتاد. لا تتناولي جرعة<br />مضاعفة لتعويض جرعة فائتة.<br />&trade; في حالة التوقف عن تناول ريزولور<br />فقد يعود الإمساك مرة أخرى. ،&trade; في حالة التوقف عن تناول ريزولور<br />إذا كانت لديك أي أسئلة أخرى عن استخدام هذا الدواء، فسألي الطبيب أو الصيدلي.<br />&trade; معلومات مهمة عن بعض مكونات ريزولور<br />على مونوهيدرات اللاكتوز. إذا أخبرك الطبيب أن جسمك لا يتحمل بعض السكريات، فاتصل &trade; يحتوي ريزولور<br />بالطبيب قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>الآثار غير المرغوب فيها&nbsp;<br />آثارًا جانبية، على الرغم من أنها لا تحدث في جميع الأفراد. عادةً تحدث &trade; مثل كل الأدوية، يمكن أن يسبب ريزولور<br />لأول مرة، وعادةً تختفي في غضون أيام قليلة. &trade; الآثار الجانبية عند بدء استخدام ريزولور<br />الآثار الجانبية الشائعة جدًا<br />قد تؤثر هذه الآثار على أكثر من شخص واحد من كل 10 أشخاص.<br />&bull; صداع<br />&bull; الغثيان<br />&bull; إسهال<br />&bull; ألم في المعدة<br />الآثار الجانبية الشائعة<br />قد تؤثر هذه الآثار على شخص واحد من كل 10 أشخاص.<br />&bull; دوخة<br />&bull; قيء<br />&bull; اضطراب الهضم (سوء الهضم)<br />&bull; نزيف في المستقيم<br />&bull; انتفاخ<br />&bull; أصوات غير معتادة بالأمعاء<br />&bull; الرغبة في التبول أكثر من المعتاد<br />&bull; تعب<br />الآثار الجانبية غير الشائعة<br />قد تؤثر هذه الآثار على شخص واحد من كل 100 أشخاص.<br />&bull; فقدان الشهية<br />&bull; رعاش<br />&bull; حمى<br />&bull; ضعف<br />&bull; ازدياد ضربات القلب (خفقان) إذا كنت تعانين من قوة ضربات القلب، فأخبري الطبيب على الفور، فقد تحتاجين إلى<br />عناية طبية.<br />في حالة تفاقم أيٍ من الآثار الجانبية، أو ملاحظة أي آثار جانبية غير المذكورة أعلاه في هذه النشرة، يُرجى إخبار الطبيب<br />أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول ونظر الأطفال.<br />بعد تاريخ انتهاء الصلاحية (الشهر والسنة) المطبوع &trade; يمكن حفظ هذا الدواء لمدة محدودة فقط. لا تستخدمي ريزولور<br />انتهاء الصلاحية)، حتى عند الحفظ السليم للدواء. ) &quot;EXP&quot; بعد علامة<br />يُحفظ في العبوة الأصلية للحماية من الرطوبة. لا يُخزن في درجة حرارة أكبر من 30 درجة مئوية.<br />يُنصح بإعادة الدواء منتهي الصلاحية إلى الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دواء لعلاج الإمساك. &trade; ريزولور<br />المكون النشط هو بروكالوبرايد.<br />على 1 ملجم بروكالوبرايد (بروكالوبرايد سكسينات). &trade; &bull; يحتوي كل قرص 1 ملجم مغطى بطبقة رقيقة من ريزولور<br />على 2 ملجم بروكالوبرايد (بروكالوبرايد سكسينات). &trade; &bull; يحتوي كل قرص 2 ملجم مغطى بطبقة رقيقة من ريزولور</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>المكونات الأخرى:<br />مونوهيدرات اللاكتوز، سيلولوز دقيق البللورات، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم،<br />ماكروجول 3000 . يحتوي القرص 2 ملجم أيضًا على ،(E هيبروميلوز، ثلاثي الأستين، وثاني أكسيد التيتانيوم ( 171<br />لون صناعي أزرق من صبغ الألومنيوم مطابق ،(E وأكسيد الحديد الأصفر ( 172 ،(E أكسيد الحديد الأحمر ( 172<br />(E لمواصفات الغذاء والأدوية والمستحضرات الطبية ( 132</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة صاحبة التسجيل/الشركة المصنعة<br />انظر العبوة الخارجية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            28 فبراير 2011
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RESOLORTM Film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains: 
-	1 mg prucalopride (equivalent to 1.321 mg prucalopride succinate). 
-	2 mg prucalopride (equivalent to 2.642 mg prucalopride succinate). For excipients, see List of Excipients. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet 
-	1 mg: white to off-white, round, biconvex tablets marked “PRU 1” on one side - 	2 mg: pink, round, biconvex tablets marked “PRU 2” on one side. 
 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESOLOR<sup>TM </sup>is indicated for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Women</em> <em>Men</em></p><p>2 mg once daily.</p><p>The safety and efficacy of Resolor for use in men has not been established in controlled clinical trials therefore Resolor is not recommended for use in men until further data becomes available.</p><p><em>Elderly (&gt; 65 years)</em></p><p>Start with one 1 mg once daily (see Pharmacokinetic Properties); if needed the dose can be increased to 2 mg once daily.</p><p>Children and adolescents</p><p>RESOLOR<sup>TM </sup>is not recommended in children and adolescents younger than 18 years until further data become available. Currently available data are described in Pharmacokinetic Properties</p><p><em>Patients with renal impairment</em></p><p>The dose for patients with severe renal impairment (GFR &lt; 30 ml/min/1.73 m<sup>2</sup>) is 1 mg once daily (see Contraindications and Pharmacokinetic Properties). No dose adjustment is required for patients with mild to moderate renal impairment.</p><p><em>Patients with hepatic impairment</em></p><p>The dose for patients with severe hepatic impairment (Child-Pugh class C) is 1 mg once daily (see Special Warnings and Special Precautions for Use and Pharmacokinetic Properties). No dose adjustment is required for patients with mild to moderate hepatic impairment.</p><p>&nbsp;</p><p>Due to the specific mode of action of prucalopride (stimulation of propulsive motility) exceeding the daily dose of 2 mg is not expected to increase efficacy.</p><p>If the intake of once daily prucalopride is not effective after 4 weeks of treatment, the patient should be re-examined and the benefit of continuing treatment reconsidered.</p><p>&nbsp;</p><p>The efficacy of prucalopride has been established in double-blind placebo controlled studies for up to 3 months. In case of prolonged treatment the benefit should be reassessed at regular intervals.</p><p>&nbsp;</p><p>Method of administration</p><p>RESOLOR<sup>TM </sup>film-coated tablets are for oral use and can be taken with or without food, at any time of the day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients. 
-	Renal impairment requiring dialysis. 
-	Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract, such as Crohn’s disease, and ulcerative colitis and toxic megacolon/megarectum. 
 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Renal excretion is the main route of elimination of prucalopride (see Pharmacokinetic Properties). A dose of 1 mg is recommended in subjects with severe renal impairment (see Posology and Method of Administration).&nbsp;<br />&nbsp;<br />Patients with severe and clinically unstable concomitant disease (e.g. liver, cardiovascular or lung disease, neurological or psychiatric disorders, cancer or AIDS and other endocrine disorders) have not been studied. Caution should be exercised when prescribing RESOLORTM to patients with these conditions. In particular RESOLORTM should be used with caution in patients with a history of arrhythmias or ischaemic cardiovascular disease.&nbsp;<br />&nbsp;<br />In case of severe diarrhea, the efficacy of oral contraceptives may be reduced and the use of an additional contraceptive method is recommended to prevent possible failure of oral contraception.&nbsp;<br />&nbsp;<br />It is unlikely that hepatic impairment will affect prucalopride metabolism and exposure in man to a clinically relevant extent. No data are available in patients with mild, moderate or severe hepatic impairment, and therefore a lower dose is recommended for patients with severe hepatic impairment (see Posology and Method of Administration).&nbsp;<br />&nbsp;<br />Men: The safety and efficacy of Resolor for use in men has not been established in controlled clinical trials therefore Resolor is not recommended for use in men until further data becomes available.&nbsp;<br />&nbsp;<br />The tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption must not take this medicinal product.&nbsp;<br />&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>In vitro </em>data indicate that prucalopride has a low interaction potential, and therapeutic concentrations of prucalopride are not expected to affect the CYP-mediated metabolism of co-medicated medicinal products. Although prucalopride may be a weak substrate for P-glycoprotein (P-gp), it is not an inhibitor of P-gp at clinically relevant concentrations.</p><p>&nbsp;</p><p>Ketoconazole (200 mg b.i.d.), a potent inhibitor of CYP3A4 and of P-gp, increased the area under the curve (AUC) of prucalopride by approximately 40%. This effect is too small to be clinically relevant and is likely attributable to inhibition of P-gp mediated renal transport. Interactions of similar magnitude as observed with ketoconazole may also occur with other potent inhibitors of P-gp such as verapamil, cyclosporine A and quinidine. Prucalopride is likely also secreted via another renal transporter(s). Inhibition of all transporters involved in the active secretion of prucalopride (including P-gp) may theoretically increase the exposure by up to 75%.</p><p>Studies in healthy subjects showed that there were no clinically relevant effects of prucalopride on the pharmacokinetics of warfarin, digoxin, alcohol and paroxetine. A 30% increase in the plasma concentrations of erythromycin was found during prucalopride co-treatment. The mechanism for this interaction is not fully known, but the available data support that this is the consequence of the high intrinsic variability in erythromycin kinetics, rather than a direct effect of prucalopride.</p><p>&nbsp;</p><p>Therapeutic doses of probenecid, cimetidine, erythromycin and paroxetine did not affect the pharmacokinetics of prucalopride.</p><p>&nbsp;</p><p>RESOLOR<sup>TM </sup>should be used with caution in patients receiving concomitant drugs known to cause QTc prolongation.</p><p>&nbsp;</p><p>Because of the mechanism of action, the use of atropine-like substances may reduce the 5-HT<sub>4 </sub>receptor mediated effects of prucalopride.</p><p>Interactions with food have not been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use during Pregnancy</p><p>Experience with prucalopride during pregnancy is limited. Cases of spontaneous abortion have been observed during clinical studies, although, in the presence of other risk factors, the relationship to prucalopride is unknown. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development (see Preclinical Safety Data). RESOLOR<sup>TM </sup>is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment with prucalopride. <em>Use during Lactation</em></p><p>Prucalopride is excreted in breast milk. However, at therapeutic doses of RESOLOR<sup>TM </sup>no effects on the breastfed newborns/infants are anticipated. In the absence of human data, it is not recommended to use RESOLOR<sup>TM </sup>during breast-feeding.</p><p>Fertility</p><p>Animal studies indicate that there is no effect on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of prucalopride on the ability to drive and use machines have been performed. RESOLOR<sup>TM </sup>has been associated with dizziness and fatigue particularly during the first day of treatment which may have an effect on driving and using machines (see Undesirable Effects).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESOLOR<sup>TM </sup>has been given orally to approximately 2700 patients with chronic constipation in controlled clinical studies. Of these patients, almost 1000 patients received RESOLOR<sup>TM </sup>at the recommended dose of 2 mg per day, while about 1300 patients were treated with 4 mg prucalopride daily. Total exposure in the clinical development plan exceeded 2600 patient years. The most frequently reported adverse reactions associated with RESOLOR<sup>TM </sup>therapy are headache and gastrointestinal symptoms (abdominal pain, nausea or diarrhea) occurring in approximately 20% of patients each. The adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. Other adverse reactions have been reported occasionally. The majority of adverse events were mild to moderate in intensity.</p><p>The following adverse reactions were reported in controlled clinical studies at the recommended dose of 2 mg with frequencies corresponding to Very common (<sub>&ge;</sub> 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&gt; 1/1000 to &lt; 1/100), Rare (&gt; 1/10000 to &lt; 1/1000) and Very rare (<sub>&le;</sub> 1/10000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are calculated based on the placebo-controlled clinical study data.</p><p><strong>Metabolism and nutrition disorders</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anorexia</p><p><strong>Nervous system disorders</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p><strong>Cardiac disorders</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations</p><p><strong>Gastrointestinal disorders</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea, diarrhea, abdominal pain</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting, dyspepsia, rectal haemorrhage, flatulence, abnormal bowel sounds</p><p><strong>Renal and urinary disorders</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pollakiuria</p><p><strong>General disorders and administration site conditions</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, malaise</p><p>&nbsp;</p><p>After the first day of treatment, the most common adverse reactions were reported in similar frequencies (incidence less than 1% different between prucalopride and placebo) during RESOLOR<sup>TM </sup>therapy as during placebo, with the exception of nausea and diarrhea that still occurred more frequently during RESOLOR<sup>TM </sup>therapy, but less pronounced (difference in incidence between prucalopride and placebo between 1 and 3%).</p><p>Palpitations were reported in 0.7% of the placebo patients, 1.0% of the 1 mg prucalopride patients, 0.7% of the 2 mg prucalopride patients and 1.9% of the 4 mg prucalopride patients. The majority of patients continued using prucalopride. As with any new symptom, patients should discuss the new onset of palpitations with their physician.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a study in healthy volunteers treatment with prucalopride was well tolerated when given in an up-titrating scheme up to 20 mg once daily (10 times the recommended therapeutic dose). An overdose may result in symptoms resulting from an exaggeration of the medicinal product&rsquo;s known pharmacodynamic effects and include headache, nausea and diarrhea. Specific treatment is not available for RESOLOR<sup>TM </sup>overdose. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted, as required. Extensive fluid loss by diarrhea or vomiting may require correction of electrolyte disturbances.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs acting on serotonin receptors, ATC code: A03AE04.</p><p>&nbsp;</p><p>Mechanism of action</p><p>Prucalopride is a dihydrobenzofurancarboxamide with enterokinetic activities. Prucalopride is a selective, high affinity serotonin (5-HT<sub>4</sub>) receptor agonist, which is likely to explain its enterokinetic effects. <em>In vitro</em>, only at concentrations exceeding its 5-HT<sub>4 </sub>receptor affinity by at least 150-fold, affinity for other receptors was detected. In rats prucalopride <em>in vivo </em>at doses above 5 mg/kg (at and above 30-70 times the clinical exposure) induced hyperprolactinaemia caused by an antagonistic action at the D2 receptor.</p><p>&nbsp;</p><p>In dogs, prucalopride alters colonic motility patterns via serotonin 5-HT<sub>4 </sub>receptor stimulation:</p><p>it stimulates proximal colonic motility, enhances gastroduodenal motility and accelerates delayed gastric emptying. Furthermore, giant migrating contractions are induced by prucalopride. These are equivalent to the colonic mass movements in humans, and provide the main propulsive force to defecation. In dogs, the effects observed in the gastrointestinal tract are sensitive to blockade with selective 5-HT<sub>4 </sub>receptor antagonists illustrating that the observed effects are exerted via selective action on 5-HT<sub>4 </sub>receptors.</p><p>&nbsp;</p><p>Clinical experience</p><p>The efficacy of prucalopride was established in three multicentre, randomised, double-blind, 12-week placebo-controlled studies in subjects with chronic constipation (n=1279 on prucalopride, 1124 females, 155 males). The prucalopride doses studied in each of these three studies included 2 mg and 4 mg once daily. The primary efficacy endpoint was the proportion (%) of subjects that reached normalisation of bowel movements defined as an average of three or more spontaneous, complete bowel movements (SCBM) per week over the 12-week treatment period. Both doses were statistically superior (p&lt;0.001) to placebo at the primary endpoint in each of the three studies, with no incremental benefit of the 4 mg over the 2 mg dose. The proportion of patients treated with the recommended dose of 2 mg prucalopride that reached an average of <sub>&ge;</sub> 3 SCBM per week was 27.8% (week 4) and 23.6% (week 12), versus 10.5% (week 4) and 11.3% (week 12) on placebo. A clinically meaningful improvement of</p><p>&ge; 1 SCBM per week, the most important secondary efficacy endpoint, was achieved in 48.1% (week 4) and 43.1% (week 12) of patients treated with 2 mg prucalopride versus 23.4% (week 4) and 24.6% (week 12) of placebo patients.</p><p>&nbsp;</p><p>In all three studies, treatment with prucalopride also resulted in significant improvements in a validated and disease specific set of symptom measures (PAC SYM), including abdominal, stool and rectal symptoms, determined at week 4 and week 12. A significant benefit on a number of Quality of Life measures, such as degree of satisfaction with treatment and with bowel habits, physical and psychosocial discomfort and worries and concerns, was also observed at both the 4- and 12-week assessment time points.</p><p>&nbsp;</p><p>Prucalopride has been shown not to cause rebound phenomena, nor to induce dependency.</p><p>&nbsp;</p><p>A thorough QT study was performed to evaluate the effects of prucalopride on the QT interval at therapeutic (2 mg) and supratherapeutic doses (10 mg) and compared with the effects of placebo and a positive control. This study did not show significant differences between prucalopride and placebo at either dose, based on mean QT measurements and outlier analysis. This confirmed the results of two placebo controlled QT studies. In double-blind clinical studies, the incidence of QT-related adverse events and ventricular arrhythmias was low and comparable to placebo.</p><p>&nbsp;</p><p>Data from open label studies up to 2.6 years offer some evidence for longer-term safety and efficacy; however, no placebo controlled efficacy data for treatments longer than 12 weeks duration are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Prucalopride is rapidly absorbed; after a single oral dose of 2 mg C<sub>max </sub>was attained in 2-3 hours. The absolute oral bioavailability is &gt;90%. Concomitant intake of food does not influence the oral bioavailability of prucalopride.</p><p>&nbsp;</p><p>Distribution</p><p>Prucalopride is extensively distributed, and has a steady-state volume of distribution (Vd<sub>ss</sub>) of 567 litre. The plasma protein binding of prucalopride is about 30%.</p><p>&nbsp;</p><p>Metabolism</p><p>Metabolism is not the major route of elimination of prucalopride. <em>In vitro</em>, human liver metabolism is very slow and only minor amounts of metabolites are found. In an oral dose study with radiolabelled prucalopride in man, small amounts of eight metabolites were recovered in urine and faeces. The major metabolite (R107504, formed by O-demethylation and oxidation of the resulting alcohol function to a carboxylic acid) accounted for less than 4% of the dose. Unchanged active substance made up about 85% of the total radioactivity in plasma and only R107504 was a minor plasma metabolite.</p><p>&nbsp;</p><p>Elimination</p><p>A large fraction of the active substance is excreted unchanged (about 60% of the administered dose in urine and at least 6% in faeces). Renal excretion of unchanged prucalopride involves both passive filtration and active secretion. The plasma clearance of prucalopride averages 317 ml/min. Its terminal half-life is about one day. Steady-state is reached within three to four days. On once daily treatment with 2 mg prucalopride steady-state plasma concentrations fluctuate between trough and peak values of 2.5 and 7 ng/ml, respectively. The accumulation ratio after once daily dosing ranged from 1.9 to 2.3. The pharmacokinetics of prucalopride is dose-proportional within and beyond the therapeutic range (tested up to 20 mg). Prucalopride o.d. displays time-independent kinetics during prolonged treatment.</p><p>&nbsp;</p><p>Special populations</p><p>Population pharmacokinetics</p><p>A population pharmacokinetic analysis showed that the apparent total clearance of prucalopride was correlated with creatinine clearance, but that age, body weight, sex or race had no influence. <em>Elderly</em></p><p>After once daily dosing of 1 mg, peak plasma concentrations and AUC of prucalopride in elderly subjects were 26% to 28% higher than in young adults. This effect can be attributed to a diminished renal function in elderly.</p><p>Renal impairment</p><p>Compared to subjects with normal renal function, plasma concentrations of prucalopride after a single 2 mg dose were on average 25% and 51% higher in subjects with mild</p><p>(Cl<sub>CR </sub>50-79 ml/min) and moderate (Cl<sub>CR </sub>25-49 ml/min) renal impairment, respectively. In subjects with severe renal impairment (Cl<sub>CR </sub>&le; 24 ml/min), plasma concentrations were 2.3 times the levels in healthy subjects (see Posology and Method of Administration and Special Warnings and Special Precautions for Use). <em>Hepatic impairment</em></p><p>Non-renal elimination contributes to about 35% of total elimination, and hepatic impairment is unlikely to affect the pharmacokinetics of prucalopride to a clinically relevant extent (see Posology and Method of Administration and Special Warnings and Special Precautions for Use).</p><p>Pediatric population</p><p>After a single oral dose of 0.03 mg/kg in pediatric patients aged between 4 and 12 years, C<sub>max </sub>of prucalopride was comparable to the C<sub>max </sub>in adults after a single 2 mg dose, while unbound AUC was 30-40% lower than after 2 mg in adults. Unbound exposure was similar over the whole age-range (4-12 years).The average terminal half-life in the pediatric subjects was about 19 hours (range 11.6 to 26.8 hours) (see Posology and Method of Administration).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development. An extended series of safety pharmacology studies with special emphasis on cardiovascular parameters showed no relevant changes in haemodynamic and ECG derived parameters (QTc) with the exception of a modest increase in heart rate and blood pressure observed in anaesthesized pigs after intravenous administration, and an increase in blood pressure in conscious dogs after bolus intravenous administration, which was not observed either in anaesthetized dogs or after oral administration in dogs reaching similar plasma levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Lactose monohydrate Microcrystalline cellulose Colloidal silicon dioxide Magnesium stearate</p><p>Coating</p><p>Hypromellose (E464)</p><p>Lactose monohydrate</p><p>Triacetin</p><p>Titanium dioxide (E171)</p><p>Macrogol 3000</p><p>Iron oxide red (E172)*</p><p>Iron oxide yellow (E172)*</p><p>FD&amp;C blue no. 2 aluminium lake (E132)*</p><p>* 2 mg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Observe expiry date on the outer pack. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C. Protect from moisture.</p><p>Keep out of reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/aluminium perforated unit dose blisters containing 7 tablets. Each pack contains 7 x 1, 14 x 1, 28 x 1 film-coated tablets.</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Shire-Move tis NV, Veedijk 58, B-2300 Turnhout, Belgium. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2011 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>